REG - Sareum Holdings PLC - Notice of Half-Year Results

Sareum HoldingsAnnouncement

15/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230315:nRSO9774Sa&default-theme=true

RNS Number : 9774S  Sareum Holdings PLC  15 March 2023

Sareum Holdings PLC

 

("Sareum" or the "Company")

 

Notice of Half-Year Results and Investor Presentation

 

Cambridge, UK, 15 March 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology
company developing next generation kinase inhibitors for autoimmune disease
and cancer, will announce its unaudited results for the six months ended 31
December 2022 on Wednesday, 22 March 2023.

 

The Company will be holding a presentation to investors on Wednesday, 22 March
2023 at 12.30 pm GMT via the Investor Meet Company ("IMC") platform.

 

Investors can sign up to Investor Meet Company for free and add to meet SAREUM
HOLDINGS PLC via:
https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
(https://www.investormeetcompany.com/sareum-holdings-plc/register-investor)

 

Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company
platform will automatically be invited.

 

A copy of the presentation will be made available on the Company's website
following the presentation.

- Ends -

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Alexandra Harrison, Head of IR                      ir@sareum.co.uk (mailto:ir@sareum.co.uk)

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Oliver Duckworth                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   0203 709 5700

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, which, is planned
to enter clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBIGDXLUBDGXS